Teladoc Health holds 2026 annual meeting; all director nominees elected

Proposal 1 — Election of Directors The stockholders of the Company elected each of the following director nominees proposed by the Company’s Board of Directors to serve until the 2027 Annual Meeting of Stockholders of the Company and until their respective successors have been duly elected and qualified. The voting results for each director nominee are set forth below. Name For Against Abstentions Broker Non-Votes Charles Divita, III 76,534,562 4,688,083 62,996 43,207,208 Sandra L. Fenwick 74,876,294 5,374,184 1,035,163 43,207,208 Catherine A. Jacobson 73,823,862 6,428,082 1,033,697 43,207,208 Kenneth H. Paulus 74,670,036 6,524,629 90,976 43,207,208 Susan R. Salka 76,279,272 4,840,123 166,246 43,207,208 David L. Shedlarz 74,640,078 5,608,770 1,036,793 43,207,208 Mark Douglas Smith, M.D., MBA 78,213,920 2,011,677 1,060,044 43,207,208 Michael S. Smith 76,313,738 4,883,881 88,022 43,207,208 David B. Snow, Jr. 67,368,308 12,899,237 1,018,096 43,207,208

Proposal 2 — Advisory Vote Approving the Compensation of the Company’s Named Executive Officers The stockholders of the Company approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The voting results are set forth below. For Against Abstentions Broker Non-Votes 71,154,268 8,973,257 1,158,116 43,207,208